Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 8/20 | 0.41 |
| ▸ | RRM2 | P31350 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.32 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24983588 | 0.77 | CCR1 (0.50) | CCR1ERN1RRM2ALDH1A1HTR2B | |
| SCHEMBL2494195 | 0.76 | CCR1 (0.48) | CCR1ERN1RRM2ALDH1A1HTR2B | |
| SCHEMBL29935362 | 0.74 | CCR1 (0.46) | CCR1ERN1RRM2ALDH1A1HTR2B | |
| SCHEMBL16742704 | 0.74 | CCR1 (0.46) | CCR1ERN1RRM2ALDH1A1HTR2B | |
| SCHEMBL1574734 | 0.74 | CCR1 (0.46) | CCR1RRM2ALDH1A1TERTTRIM24 | |
| SCHEMBL17049068 | 0.74 | CCR1 (0.46) | CCR1RRM2ALDH1A1HTR2BTERT | |
| SCHEMBL15104564 | 0.74 | CCR1 (0.46) | CCR1ERN1RRM2ALDH1A1TERT | |
| SCHEMBL25207516 | 0.74 | CCR1 (0.46) | CCR1RRM2ALDH1A1TERTTRIM24 | |
| SCHEMBL5490830 | 0.69 | PRKDC (0.44) | CCR1ERN1ALDH1A1KDM4ETRIM24 | |
| SCHEMBL16563898 | 0.69 | CCR1 (0.42) | CCR1ERN1ALDH1A1HTR2BTERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765039-B2 | Biaryl derivatives as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-09-19 | — | — | US | disclosed |
| US-9765039-B2 | Biaryl derivatives as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-09-19 | — | — | US | disclosed |
| US-9765039-B2 | Biaryl derivatives as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-09-19 | — | — | US | disclosed |
| EP-2504323-B1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN INC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-8828973-B2 | Compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8828973-B2 | Compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8828973-B2 | Compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20140221317-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221317-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221317-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140140956-A1 | BIARYL DERIVATIVES AS BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2014-05-22 | — | — | US | disclosed |
| US-8703745-B1 | Compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20140107075-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20130157982-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130157982-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130157982-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8440644-B2 | Compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2504323-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | Allergan, Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| US-20110212925-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| WO-2011066184-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107075-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | S1PR1, S1PR3, S1PR2 | CCR1 1051/4885ERN1 1575/4885RRM2 1436/4885 |
| US-20110212925-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | S1PR1, S1PR3, S1PR2 | CCR1 1051/4885ERN1 1575/4885RRM2 1436/4885 |
| US-20140140956-A1 | BIARYL DERIVATIVES AS BROMODOMAIN INHIBITORS | BRDT, BRD3, BRD4 | CCR1 3776/4885ERN1 1878/4885RRM2 1513/4885 |
| US-20140221317-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | S1PR1, S1PR3, S1PR2 | CCR1 1051/4885ERN1 1575/4885RRM2 1436/4885 |
| US-20130157982-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | S1PR1, S1PR3, S1PR2 | CCR1 1051/4885ERN1 1575/4885RRM2 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.